Methylphenidate for attention-deficit/hyperactivity disorder: Too much of a good thing?

Affiliations

¹ Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand roger.mulder@otago.ac.nz.
² Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
³ University of Canterbury, Christchurch, New Zealand.
⁴ Discipline of Psychiatry, Kolling Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia.

Editorial

Roger Mulder et al. Aust N Z J Psychiatry. 2016 Feb.

. 2016 Feb;50(2):113-4.

doi: 10.1177/0004867415626823.

¹ Department of Psychological Medicine, University of Otago - Christchurch, Christchurch, New Zealand roger.mulder@otago.ac.nz.
² Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
³ University of Canterbury, Christchurch, New Zealand.
⁴ Discipline of Psychiatry, Kolling Institute, Sydney Medical School, University of Sydney, Sydney, NSW, Australia CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, St Leonards, NSW, Australia.

No abstract available

Comment on

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.